| Description | Aligeron is a non-selective prostaglandin (PG) antagonist that inhibits PGF2α- and PGE2-induced decreases in blood pressure in cats, and can be used to inhibit PGF2α-induced diarrhea in mice and PGE2-induced paw edema in rats.Aligeron is known to have an antioxidant-protective effect against vascular complications. |
| In vitro | Aligeron demonstrates a wide-ranging spectrum of antagonistic activity against various spasmogens in diverse isolated organs. In experiments conducted on the isolated perfused rabbit artery, the antagonistic effects of Aligeron against the vasoconstrictor impacts of noradrenaline and adrenaline are evident.[1]]The effect of Aligeronin in vitro lacks selectivity and is probably due to interference with the action of Ca2+.[3] |
| In vivo | Aligeron(5 mg/kg; i.v.) increases cortical resistance to hypoxia and accelerates the recovery of cortical bioelectrical activity In hypoventilation hypoxia. Aligerons show a protective effect in KCl- and AMP-induced depressions manifested, And show a decrease in the degree and duration of the depression.[2] |
| molecular weight | 292.42 |
| Molecular formula | C20H24N2 |
| CAS | 70713-45-0 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: Soluble |
| References | 1. Miyares K, et al. Antagonistic activity of aligeron and papaverine against different smooth muscle stimuli. Methods Find Exp Clin Pharmacol. 1985 Sep;7(9):473-6. 2. Dimov S, et al. Effect of aligeron and cinnarizine in models of general and local depression of the cortical bioelectrical activity in cats. Methods Find Exp Clin Pharmacol. 1983;5(2):89-95. 3. Nikolov R, et al. Study on the prostaglandin antagonistic activity of aligeron and piracetam. Methods Find Exp Clin Pharmacol. 1982 Aug-Sep;4(6):387-95. |